Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO-Reference-Cited by-同舟云学术

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO

Published:2017-12-05 Issue:1 Volume:10 Page:55-61
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Mueller Ina¹,Ehlert Karoline¹,Endres Stefanie¹,Pill Lena¹,Siebert Nikolai¹,Kietz Silke¹,Brock Penelope²,Garaventa Alberto³,Valteau-Couanet Dominique⁴,Janzek Evelyne⁵,Hosten Norbert⁶,Zinke Andreas⁶,Barthlen Winfried⁷,Varol Emine⁷,Loibner Hans⁵,Ladenstein Ruth⁸,Lode Holger N.¹^ORCID

Affiliation:

1. Department of Pediatric Oncology, University Medicine Greifswald, Greifswald, Germany

2. Great Ormond Street Hospital, Department of Pediatric Hematology and Oncology, London, United Kingdom

3. Department of Pediatric Hematology and Oncology, Gaslini Institute, Genova Italy

4. Department of Pediatric and Adolescent Oncology Villejuif, Gustave Roussy Université Paris-Sud, France

5. Apeiron Biologics, Vienna, Austria

6. Department of Radiology and Nuclear Medicine, University Medicine Greifswald, Greifswald, Germany

7. Department of Pediatric Surgery, University Medicine Greifswald, Greifswald, Germany

8. St. Anna Children's Hospital, Department of Pediatric Hematology and Oncolgoy, Vienna, Austria

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2017.1402997

Reference21 articles.

1. Neuroblastoma: developmental biology, cancer genomics and immunotherapy

2. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

3. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

4. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice

5. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects;Frontiers in Oncology;2024-05-15

2. Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma;Pediatric Hematology/Oncology and Immunopathology;2024-04-17

3. GD2-targeting therapy: a comparative analysis of approaches and promising directions;Frontiers in Immunology;2024-03-15

4. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3;Cancer Immunology, Immunotherapy;2024-01

5. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System;Pediatric Drugs;2023-12-28